Loading
A phase 1 trial of FID-022 run by Fulgent Pharma LLC., now recruiting.
Study of FID-022 in Participants With Advanced Solid Tumors is a phase 1 interventional study registered as NCT06694480 by Fulgent Pharma LLC., with 24 participants planned, started 2025-07-03. Conditions recorded: Advanced Solid Tumors. Interventions recorded: FID-022.
Shares Fulgent Genetics, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Fulgent Genetics and the tag pipeline.
Shares Fulgent Genetics and the tag pipeline.
Shares Fulgent Genetics and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/